Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm NEW YORK , July 18, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Amylyx insiders caused the company to misrepresent or fail to disclose that (i) RELYVRIO's commercial prospects were overstated; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) accordingly, RELYVRIO's prescription rate was also overstated; (v) insiders attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO's prescription data; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday? Amylyx Pharmaceuticals Inc (NASDAQ: AMLX ) acquired avexitide from Eiger BioPharmaceuticals Inc (OTC: EIGRQ ) for $35.1 million . Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia. The FDA has granted avexitide Breakthrough Therapy Designation for both indications, Rare Pediatric Disease Designation in congenital HI, and Orphan Drug Designation for hyperinsulinemic hypoglycemia (which includes PBH and congenital HI). Also Read: Amylyx Pharmaceuticals’ Investigational Drug Shows Improved Pancreatic Function In … Full story available on Benzinga.com
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday? Amylyx Pharmaceuticals Inc AMLX acquired avexitide from Eiger BioPharmaceuticals Inc EIGRQ for $35.1 million.
Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Avexitide Acquisition Conference Call July 10, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Joshua Cohen - Co-Chief Executive Officer Camille Bedrosian - Chief Medical Officer James Frates - Chief Financial Officer Conference Call Participants Corinne Jenkins - Goldman Sachs Michael DiFiore - Evercore ISI Graig Suvannavejh - Mizuho Securities Charlie Yang - Bank of America Merrill Lynch Joel Beatty - Robert W. Baird & Company Ananda Ghosh - H.C.
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger BioPharmaceuticals. To access the conference call, please dial +1 (800) 836-8184 (U.S. and Canada) or +1 (646) 357-8785 (international) Jetzt den vollständigen Artikel lesen
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition No summary available.
Amylyx inks deal to buy Eiger’s GLP-1 targeting drug Amylyx Pharmaceuticals (AMLX) stock gains on deal to acquire Phase 3-ready GLP-1 receptor antagonist from Eiger BioPharmaceuticals (EIGRQ). REad more here.
Amylyx to buy bankrupt Eiger''s experimental drug to treat low blood sugar Amylyx Pharmaceuticals has agreed to buy the rights to bankrupt drugmaker Eiger BioPharmaceuticals'' experimental drug for low blood sugar in a $35.1 million deal, Eiger said in a filing on Friday.
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar Amylyx Pharmaceuticals has agreed to buy the rights to bankrupt drugmaker Eiger BioPharmaceuticals' experimental drug for low blood sugar in a $35.1 million deal, Eiger said in a filing on Friday.
Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference.